Welcome to our dedicated page for Halozyme Thrp news (Ticker: HALO), a resource for investors and traders seeking the latest updates and insights on Halozyme Thrp stock.
Halozyme Therapeutics, Inc. develops and commercializes drug-delivery technologies for subcutaneous administration of biologics and other injectable therapies. News about HALO commonly covers ENHANZE licensing agreements, Hypercon and Surf Bio hyperconcentration collaborations, partner product regulatory approvals, royalty-based revenue updates, and financial guidance.
The company also reports developments tied to its proprietary products Hylenex and XYOSTED, drug-device combination products using auto-injector technologies, and collaborations with pharmaceutical and biotechnology companies in oncology, inflammatory disease and other therapeutic areas.
Halozyme (NASDAQ: HALO) announced a proposed offering of $650 million principal of convertible senior notes due 2031 and $650 million principal of convertible senior notes due 2032, with initial purchaser options of up to $100 million additional for each series.
The notes will be senior unsecured, accrue interest semi-annually, and mature Feb 15, 2031 and Nov 15, 2032. Conversions may be settled in cash and, at the company's election, shares of common stock. The company plans capped call transactions and expects to use proceeds for capped calls, repurchases of existing 2027 and 2028 convertible notes, and general corporate purposes.
Halozyme (NASDAQ: HALO) reported record Q3 2025 results with total revenue $354.3M (22% YoY) and royalty revenue $236.0M (52% YoY). GAAP net income was $175.2M and GAAP diluted EPS was $1.43; adjusted EBITDA was $248.2M. The company raised 2025 guidance to $1.30–1.375B total revenue, $850–880M royalties, $885–935M adjusted EBITDA, and $6.10–6.50 non-GAAP diluted EPS.
Halozyme announced a planned $750M upfront acquisition of Elektrofi with up to three $50M regulatory milestones and a CFO transition plan; share repurchases used $92.3M to buy ~1.7M shares YTD. Cash and marketable securities were $702.0M on Sept 30, 2025.
Halozyme (NASDAQ: HALO) will release its third quarter 2025 financial and operating results on Monday, November 3, 2025 following the close of trading.
The company will host a conference call on Monday, November 3, 2025 at 1:30 p.m. PT / 4:30 p.m. ET to discuss results. The call requires pre-registration via the provided link and a live webcast and replay will be available in the Investors section of Halozyme's website.
Halozyme (NASDAQ: HALO) has announced a definitive agreement to acquire Elektrofi for $750 million upfront plus up to $150 million in milestone payments. The acquisition centers on Elektrofi's breakthrough Hypercon™ technology, enabling biologic formulations with 400-500 mg/ml concentrations - up to 5 times higher than current standards.
The strategic acquisition expands Halozyme's drug delivery capabilities with long-term IP protection into the 2040s. Two of Elektrofi's partners are expected to begin clinical development of Hypercon™ formulated products by end of 2026, with royalty revenue projected to start in 2030. The transaction is expected to close in Q4 2025 and will be less than 5% dilutive to Non-GAAP EPS over medium-term.
Halozyme reaffirmed its 2025 guidance with total revenue of $1,275-$1,355 million and royalty revenue of $825-$860 million.
Halozyme Therapeutics (NASDAQ: HALO) announced its participation in three upcoming investor conferences in September 2025. CEO Dr. Helen Torley and VP of Investor Relations Tram Bui will represent the company.
The schedule includes presentations at the Wells Fargo Healthcare Conference in Boston on September 4, the Morgan Stanley Global Healthcare Conference in New York on September 8, and the H.C. Wainwright Global Investment Conference in New York on September 9. Live audio webcasts will be available on Halozyme's website with 90-day replay access.
Halozyme (NASDAQ: HALO) reported exceptional Q2 2025 results with total revenue increasing 41% YOY to $326 million and royalty revenue growing 65% YOY to $206 million. Net income surged 77% YOY to $165 million, while adjusted EBITDA rose 65% YOY to $226 million.
The company raised its 2025 guidance, projecting total revenue of $1,275-$1,355 million (26-33% YOY growth) and adjusted EBITDA of $865-$915 million (37-45% YOY growth). Growth was driven by three blockbuster therapies: DARZALEX SC, Phesgo, and VYVGART Hytrulo.
Halozyme announced its third $250 million share repurchase tranche under the $750 million authorized plan, completing $303 million in share repurchases during Q2 2025.
Halozyme Therapeutics (NASDAQ: HALO) announced that Janssen-Cilag received European Commission approval for DARZALEX Faspro®, co-formulated with Halozyme's ENHANZE® technology, for treating high-risk smouldering multiple myeloma (SMM) in adult patients.
This approval marks a significant shift from the current "Watch and Wait" standard of care, enabling early intervention in SMM patients before disease progression. The approval is based on the Phase 3 AQUILA study evaluating fixed-duration monotherapy daratumumab SC versus active monitoring in high-risk SMM patients.
Halozyme Therapeutics (NASDAQ: HALO) has scheduled the release of its second quarter 2025 financial and operating results for Tuesday, August 5, 2025, after market close. The company will host a conference call the same day at 1:30 p.m. PT/4:30 p.m. ET to discuss the results.
Investors can access the conference call through pre-registration and join the live webcast through Halozyme's investor relations website. A replay will also be available on the corporate website.
Halozyme Therapeutics (NASDAQ: HALO) has announced its addition to the U.S. large-cap Russell 1000® Index, effective after market close on June 27th, 2025, as part of FTSE Russell's annual index reconstitution. The Russell 1000® Index comprises approximately 1,000 of the largest U.S. securities based on market capitalization and serves as a key benchmark for large-cap stock performance.
According to CEO Dr. Helen Torley, this inclusion reflects the company's leadership in rapid large-volume subcutaneous drug delivery and their track record of durable top-and-bottom line growth. The membership in the Russell 1000® Index will remain in place for one year.